Beyond Numbers: Uses and Value of In-Trial Interview Data for Regulatory and Health Technology Assessment (HTA) Decision Making
Open Access
- 2 February 2026
- journal article
- review article
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 19 (3) , 385-405
Abstract
This research explores the growing importance of qualitative in-trial research (ITR) in regulatory and health technology assessment (HTA) decision making. Since 2020, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) have emphasized incorporating patient experience data into drug development and approval. We reviewed regulatory guidance documents, drug approval records, and HTA reports from January 2017 to March 2025. This included labels and reviews for new drug applications from the FDA and EMA, the Patient-Focused Drug Development guidance series, guidance on rare diseases, oncology, and gene therapy, and methodological guidance from HTA bodies in Scotland, the UK, France, Germany, Italy, and Spain. From more than 1000 drug applications assessed by both regulatory agencies, only ten and eight products (from the FDA and EMA, respectively) included ITR, with 55% of these for rare diseases. Both agencies used ITR data to gain insights into symptoms and patient experiences, the relevance of patient-reported outcome concepts, and meaningful changes in symptoms or treatment benefits; and to support the interpretation of meaningful score or endpoint changes. Two products included ITR data in both FDA and EMA reviews/labels. Three HTA bodies published guidance documents on qualitative research, with only two products out of eight reviewed including qualitative data in HTA reports.Despite increasing use, ITR in regulatory submissions and HTA reviews remains limited. Early planning and alignment of ITR objectives with regulatory and HTA requirements are needed to enhance the relevance and impact of qualitative evidence in drug development and healthcare decision making.Keywords
Funding Information
- PPD Evidera Patient Centered Research
This publication has 29 references indexed in Scilit:
- Patients’ Experiences of Atopic Dermatitis and Nemolizumab Treatment: An In-Trial Interview Study Embedded in a Phase 3 Clinical Trial (ARCADIA)The Patient - Patient-Centered Outcomes Research, 2025
- Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: A U.S. regulatory perspectiveAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2025
- Qualitative In-trial Interviews: Methods, Challenges, and Best PracticeThe Patient - Patient-Centered Outcomes Research, 2025
- The Limitations of EQ-5D as a Clinical Outcome Assessment ToolThe Patient - Patient-Centered Outcomes Research, 2024
- A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy ResultsAmerican Journal of Clinical Dermatology, 2022
- Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 DiabetesThe Patient - Patient-Centered Outcomes Research, 2022
- Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant DepressionThe Patient - Patient-Centered Outcomes Research, 2019
- Exploring the Diabetic Gastroparesis Patient Experience: Patient Exit InterviewsAdvances in Therapy, 2017
- Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview ApproachClinical Therapeutics, 2016
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990